



Universiteit
Leiden
The Netherlands

Next generation lipopeptide antibiotics

Al Ayed, U.K.

Citation


Al Ayed, U. K. (2024, January 23). *Next generation lipopeptide antibiotics*. Retrieved from <https://hdl.handle.net/1887/3714346>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3714346>

Note: To cite this publication please use the final published version (if applicable).



Chapter 3

Synthesis and Structure–Activity Relationship Studies of N-terminal Analogues of the Lipopeptide Antibiotics Brevicidine and Laterocidine

Abstract

The brevicidine and laterocidine family of lipopeptide antibiotics exhibit strong activity against multidrug-resistant Gram-negative bacteria, while showing low propensity to induce resistance. Both peptides feature a branched lipid tail on the N-terminal residue, which for brevicidine is chiral. Here, we report the synthesis and biological evaluation of a library of brevicidine and laterocidine analogues wherein the N-terminal lipid is replaced with linear achiral fatty acids. Optimal lipid chain lengths were determined and new analogues with strong activity against colistin-resistant *E. coli* produced.

Parts of this chapter have been published in RSC Medicinal Chemistry:

Ballantine, R. D.*; Al Ayed, K.*; Bann, S. J.; Hoekstra, M.; Martin, N. I.; Cochrane, S. A. Synthesis and Structure-Activity Relationship Studies of N-Terminal Analogues of the Lipopeptide Antibiotics Brevicidine and Laterocidine. *RSC Med. Chem.* **2022**, 00, 1–3. <https://doi.org/10.1039/D2MD00281G>

Parts of the data in this chapter are part of a patent:

"Antibiotic natural product analogues"; Cochrane, S.A.; Ballantine, R. D.; Martin, N. I.; Al Ayed, K.; Hoekstra, M.; Zamarbide Losada, S.D.; Priority Date: 28 January 2021; Published: 4 August 2022; WO2022162332A1

*Authors contributed equally

Introduction

Antimicrobial resistance (AMR) is set to become a major crisis within our lifetime. In addition to the economic costs, it is estimated that the number of deaths caused by AMR will rise to 10 million annually by 2050.¹ In fact, the number of deaths attributable to bacterial AMR surpassed the yearly deaths caused by breast cancer in 2019.² Given the pressing need for new antibacterial agents, synthesis and structure-activity relationship (SAR) studies with novel lead compounds remain valuable strategies for addressing the rising tide of AMR.

Non-ribosomal lipopeptides represent a gold mine of potential antimicrobials with desirable therapeutic advantages, including strong activity against multidrug-resistant bacteria, multifaceted modes of action,³ and superior proteolytic stability when compared to ribosomal antimicrobial peptides.⁴⁻⁷ Their superior stability arises from the presence of D-amino acids and/or macrocyclic motifs, both of which improve proteolytic stability. Lipopeptides are secondary metabolites produced by non-ribosomal peptide synthetases (NRPSs), and are often N-acylated with a lipid tail.⁸ The lipids are biosynthetically derived from the branched amino acids (valine, leucine and isoleucine), therefore it is common that bacterial lipopeptides feature a similarly branched acyl group.⁹ Owing to the synthetic challenge and expense associated with incorporating these features into peptide synthesis, a common focus of SAR studies is to vary the N-terminal lipid tail. Lipid tail libraries have been created for many lipopeptides, including tridecaptins,¹⁰ paenibacterin,⁷ cerexin A₁¹¹ and polymyxins.¹²

Brevicidine (**1**) and laterocidine (**2**) (Fig. 1) are two novel peptides that were recently reported by Li *et al.* following a biosynthetic gene cluster mining strategy.¹³ Given their strong antimicrobial activity against Gram-negative bacteria (including colistin-resistant *E. coli*), along with their low cytotoxicity and low propensity to induce resistance, we recently developed methods to access both brevicidine and laterocidine by solid-phase peptide synthesis (SPPS).¹⁴ The ability to synthesize this family of lipopeptides has allowed for the possibility of SAR studies including the structurally related relacidines.¹⁵ Brevicidine (**1**) and laterocidine (**2**) each feature an N-terminal acyl chain; 4-methylhexanoyl in the former and 6-methyloctanoyl in the latter. Herein, we report the development of novel N-terminal lipid analogues of brevicidine and laterocidine with strong and selective activity against Gram-negative bacteria.

Results and Discussion

Lipid analogues were synthesized following our previously reported methods.¹⁴ Briefly: for analogues of brevicidine, Fmoc-Ser-OAllyl was first loaded on to 2-chlorotrityl (CT) chloride resin via the side chain and standard Fmoc-SPPS was performed to synthesize the tetrapeptide (**4**). Allyl ester deprotection, followed by an on-resin modified Yamaguchi esterification afforded the macrocyclic lactone portion of the peptide, which was subsequently extended through the N-terminus via SPPS to obtain the desired analogues. Similarly, for analogues of laterocidine, Fmoc-Asp-OAllyl was first loaded onto Rink Amide (RA) resin via its side chain. The allyl group was next removed and H-Gly-OAllyl was coupled after which SPPS was used to obtain linear pentapeptide (**7**). An on-resin Steglich esterification between the free hydroxyl of threonine and Alloc-Gly-OH was then performed. Both allyl and Alloc groups




Fig. 1. Structures of brevicidine (1) and Laterocidine (2). N-terminal lipid tails are highlighted in blue and structural differences between the two lipopeptides in red.


were subsequently removed followed by an on-resin macrolactamization which yielded the laterocidine macrocycle. The cyclic intermediate was then further elaborated through to the N-terminus by SPPS. Natural brevicidine has a chiral 4-methylhexanoyl lipid tail, the configuration of which has not been previously reported. This likely has an (*S*)-configuration as such lipids are often derived from isoleucine.⁸ As chiral lipids are expensive and/or must be chemically synthesized, we chose to synthesise lipid tail analogues containing cheaper, commercially available lipids. The brevicidine and laterocidine variants prepared included unacylated peptides (9 & 18) and C2 – C16 lipidated brevicidine (10 – 17) and laterocidine (19 – 26) analogues, with lipid length incrementally increasing by two carbons for each analogue. Peptides were synthesized in overall yields ranging between 5-27% (after HPLC purification).

The minimum inhibitory concentrations (MICs) of brevicidine and laterocidine analogues were determined against a panel of clinically relevant ESKAPE pathogens; *Escherichia coli* (*E. coli*), *Klebsiella pneumoniae* (*K. pneumoniae*), *Acinetobacter baumannii* (*A. baumannii*), *Pseudomonas aeruginosa* (*P. aeruginosa*) and *Staphylococcus aureus* (*S. aureus*), which cause the majority of nosocomial infections in the United States.¹⁶ Notably, while colistin (polymyxin E) is used as a last-resort antibiotic in the treatment of infections caused by many Gram-negative bacteria, the emergence of plasmid-borne genes conferring colistin resistance (*mcr*) threatens to render this drug ineffectual.¹⁷ In this resistance mechanism, the polymyxin target (Lipid A) is modified, reducing binding affinity. For this reason, a strain of colistin-resistant *E. coli* carrying the *mcr-1* gene was also included in the panel.


Table 1. Antimicrobial activity of brevicidine and laterocidine analogues 9 – 26.

Compound	Lipid Chain length	Antimicrobial Activity ($\mu\text{g/mL}$)						Hemolytic Activity (%)
		<i>E. coli</i> ATCC 25922	<i>E. coli</i> ATCC 2 5922 MCR-1	<i>K. pneumoniae</i> ATCC 1 3883	<i>A. baumannii</i> ATCC 17961	<i>P. aeruginosa</i> PAO1	<i>S. aureus</i> USA300	
1	C7	4	4	2	4	8	>32	0.8
9	H	>32	>32	>32	>32	16	>32	0.2
10	C2	>32	>32	>32	>32	8	>32	0.2
11	C4	32	32	8	32	16	>32	0.1
12	C6	8	8	4	16	>32	>32	0.3
13	C8	16	16	16	16	8	>32	0.4
14	C10	4	4	4	4	8	32	6.2
15	C12	8	8	8	4	16	32	13.3
16	C14	16	16	32	4	32	>32	18.0
17	C16	>32	>32	>32	32	>32	>32	13.3
2	C9	2	2	2-4	2	4	>32	0.4
18	H	>32	>32	>32	>32	>32	>32	0.2
19	C2	>32	>32	>32	>32	16	>32	0.2
20	C4	16	32	32	>32	8	>32	0.3
21	C6	4	8	8	16	4	>32	0.2
22	C8	2	2	2	4	2	>32	0.2
23	C10	2	2	2-4	2	2	>32	2.1
24	C12	4	4	8	2	8	32	21.5
25	C14	8	8	8	2	8	16	56.2
26	C16	32	32	>32	4	32	32	46.1
Colistin	C8/C9	0.5	8	0.5	≤ 0.25	4	>32	<0.1
0.1% TX100	ND	ND	ND	ND	ND	ND	ND	100

ND = not determined. All assays run in triplicate. [Peptide] in hemolytic assays = 64 $\mu\text{g/mL}$. Additional strain information in supplementary information.




9: $R_1 = \text{H}$; 10: $R_1 = \text{C}(\text{O})\text{CH}_3$; 11: $R_1 = \text{C}(\text{O})\text{C}_3\text{H}_7$; 12: $R_1 = \text{C}(\text{O})\text{C}_6\text{H}_{11}$; 13: $R_1 = \text{C}(\text{O})\text{C}_7\text{H}_{15}$; 14: $R_1 = \text{C}(\text{O})\text{C}_9\text{H}_{19}$; 15: $R_1 = \text{C}(\text{O})\text{C}_{11}\text{H}_{23}$; 16: $R_1 = \text{C}(\text{O})\text{C}_{13}\text{H}_{27}$; 17: $R_1 = \text{C}(\text{O})\text{C}_{15}\text{H}_{31}$;



18: $R_2 = \text{H}$; 19: $R_2 = \text{C}(\text{O})\text{CH}_3$; 20: $R_2 = \text{C}(\text{O})\text{C}_2\text{H}_5$; 21: $R_2 = \text{C}(\text{O})\text{C}_6\text{H}_{11}$; 22: $R_2 = \text{C}(\text{O})\text{C}_7\text{H}_{15}$; 23: $R_2 = \text{C}(\text{O})\text{C}_9\text{H}_{19}$; 24: $R_2 = \text{C}(\text{O})\text{C}_{11}\text{H}_{23}$; 25: $R_2 = \text{C}(\text{O})\text{C}_{13}\text{H}_{27}$; 26: $R_2 = \text{C}(\text{O})\text{C}_{15}\text{H}_{31}$;

Synthesis and Structure–Activity Relationship Studies of N-terminal Analogues of the Lipopeptide Antibiotics Brevicidine and Laterocidine



Scheme 1. On-resin syntheses of brevicidine (1) (top) laterocidine (2) (bottom). CT: 2-Chlorotrityl chloride resin, RA: Rink amide resin.

For the brevicidine lipid analogues, H-Brev (9), C2-Brev (10) and C16-Brev (17) showed complete ablation of antimicrobial activity (>32 µg/mL). The latter could possibly be due to reduced solubility of the peptide in Mueller Hinton broth (MHB), despite using DMSO as an additive, or activity could be diminished by hydrophobic self-aggregation interfering with the peptide's ability to interact with the bacterial membrane. Inversely, peptides lacking a lipid tail or with a very short lipid are likely unable to insert into the bacterial membrane thus limiting their ability to disrupt the membrane or self-permeabilise through to the periplasm.¹⁸ A similar observation has been made for unacylated analogues of polymyxin B and colistin which display no antimicrobial activity, despite retaining the ability to efficiently bind with high specificity to lipopolysaccharide (LPS).¹⁸ Notably, our lipid scan with brevicidine and laterocidine revealed an apparent double “sweet-spot” in activity with C6-Brev (12), which generally showed a two-fold decrease in activity across strains, and C10-Brev (14) which maintained comparable activity to Brevicidine (1). C10-Brev (14) likely has similar hydrophobic properties to the natural branched C7 lipid in Brev, whereas C8-Brev (13) is less hydrophobic and less active. The higher activity of C6 vs C8 was unexpected but could

be due to improved solubility. In the case of the laterocidine analogues, a broader increase in antimicrobial activity was observed for analogues **20** – **25** with C8-Lat (**22**) and C10-Lat (**23**) exhibiting the same activity as Laterocidine (**2**).

H-Lat (**18**), C2-Lat (**19**) and C16-Lat (**26**) showed a marked decrease in activity – with the exception of C16-Lat (**26**) against *A. baumannii* (4 µg/mL). The more hydrophobic analogues are likely less active due to their poorer solubility in aqueous media. Gratifyingly, the activities of the brevicidine and laterocidine analogues against *E. coli* were unaffected by the presence of the *mcr-1* resistance gene, paralleling the early *in vitro* results by Li *et al.*¹³ These findings further underscore the potential for this class of lipopeptide antibiotics to be developed as a therapeutic alternative against drug-resistant infections.

Having ascertained the antimicrobial activity of all synthetic peptides against a panel of ESKAPE pathogens, we next assessed their mammalian toxicity with hemolytic assays using sheep red blood cells. The % hemolysis for all peptides at 64 µg/mL was determined, with the hemolysis induced by the surfactant 0.1% Triton X-100 taken as 100%. The peptide concentration used is 32x the MIC of the most potent analogues. Hemolysis was <1% for all analogues with a C8 chain or shorter, including the strongest antibacterial peptide C8-Lat (**22**). Hemolytic activity increased up to C14 (>50% for C14-Lat) and then decreased at longer chain lengths, perhaps due to decreased solubility of peptides or aggregation.

Conclusions

In summary, a library of *N*-terminal lipid analogues was generated for brevicidine (**9** – **17**) and laterocidine (**18** – **26**) using our previously established synthetic approaches. The peptides were assayed *in vitro* against a panel of ESKAPE pathogens to identify analogues with comparable activities to synthetic brevicidine (**1**) and laterocidine (**2**). The substitution with a decanoyl tail in both brevicidine (**14**) and laterocidine (**23**) had no effect on the antimicrobial activity, including colistin-resistant *E. coli*. This strong activity against drug-resistant Gram-negative bacteria coupled with the reduced synthetic cost highlights these analogues as potential therapeutic candidates for future development.

Experimental methods

Materials

Brevicidine Analogues. All proteinogenic Fmoc-amino acids used in this study were purchased from CEM. The remaining Fmoc-amino acids, including Fmoc-D-Trp(Boc)-OH, Fmoc-D-Tyr(tBu)-OH and Fmoc-D-Asn(Trt)-OH were purchased from Fluorochem. Fmoc-D-Orn(Boc)-OH was purchased from Merck. Fmoc-L-Orn(Boc)-OH was purchased from ChemImpex. Fmoc-Ser-OAllyl,¹⁹ Fmoc-Asp-OAllyl,²⁰ TFA·H₂N-Gly-OAllyl²¹ were synthesized according to referenced literature procedures. Acetic anhydride, butyric acid, decanoic acid and dodecanoic acid were purchased from Alfa Aesar. Hexanoic acid and octanoic acid were purchased from Sigma-Aldrich. Myristic acid was sourced from the C6 to C14 Fatty Acid Kit by Matreya Inc. Palmitic acid was purchased from Fluorochem. [Bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium-3-oxidhexafluorophosphate (HATU),

trifluoroacetic acid (TFA) and triisopropylsilane (TIPS) were also purchased from Fluorochem. 2-Chlorotrityl chloride resin and diisopropylethylamine (DIPEA) were purchased from Sigma-Aldrich. HPLC grade acetonitrile (MeCN), dichloromethane (CH_2Cl_2) and dimethylformamide (DMF) were purchased from Merck. All chemicals were used without further purification.

Laterocidine analogues. Fmoc-L-Orn(Boc)-OH and Fmoc-D-Orn(Boc)-OH were purchased from Combi-Blocks. All other Fmoc-amino acids and the Rink amide MBHA resin were purchased from P3 BioSystems. Acetic anhydride, butyric acid, lauric acid, myristic acid, palmitic acid, sodium diethyldithiocarbamate trihydrate and pyridine were purchased from Acros Organics. Hexanoic acid, octanoic acid and decanoic acid were purchased from Alfa Aesar. ((1H-Benzo[d][1,2,3]triazol-1-yl)oxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), N,N-Diisopropylcarbodiimide (DIC) and triisopropylsilane (TIPS) were purchased from Manchester Organics. 4-Dimethylaminopyridine (DMAP) was purchased from Sigma Aldrich. Diisopropylethylamine (DIPEA), piperidine, trifluoroacetic acid (TFA) and dimethyl sulfoxide (DMSO) were purchased from Carl Roth. Dichloromethane (CH_2Cl_2) and petroleum ether were purchased from VWR Chemicals. Acetonitrile (MeCN), dimethylformamide (DMF) and methyl tertiary-butyl ether (MTBE) were purchased from Biosolve. Tetrakis(triphenylphosphine)palladium(0) and phenylsilane were purchased from Fluorochem.

Antimicrobial testing

Colistin sulfate was purchased from Activate Scientific. Kanamycin monosulfate was purchased from MP Biomedicals. *E. coli* ATCC 25922, *S. aureus* USA300 (ATCC BAA1717), *K. pneumoniae* ATCC 13883 and *A. baumannii* ATCC 17961 belong to the American Type Culture Collection (ATCC). *P. aeruginosa* PAO1 was kindly provided by L.H.C. Quarles Van Ufford, Utrecht University, Utrecht, The Netherlands. *E. coli* ATCC 25922 MCR-1 was transfected in house using the pGDP2-MCR1 plasmid kindly provided by Yong-Xin Li, The University of Hong Kong, Hong Kong, China. Sheep blood agar plates (Ref. PB5039A) were purchased from Thermo Scientific. Tryptic soy broth (Ref. 02-200-500) was purchased from Scharlab. Mueller-Hinton broth (Ref. X927.1) was purchased from Carl Roth. Polypropylene 96-wells plates (Ref. 3879) were purchased from Corning.

General procedure for manual peptide synthesis

Brevicidine analogues. Analogues of brevicidine were synthesized according to our previously reported synthesis.¹⁴ To a flame dried 50 mL round bottom flask was added Fmoc-Ser-Oallyl (220 mg, 0.600 mmol) and dry dichloromethane (CH_2Cl_2) (10.0 mL). 2-Chlorotrityl (CT) chloride resin (2.00 g, 0.81 mmol g^{-1}) and DIPEA (420 μL , 2.40 mmol) were added. The suspension was stirred under argon for 24 h at 45 °C, after which the resin was filtered through a manual SPPS vessel and washed with CH_2Cl_2 (3 x 10 mL). The resin was then capped by adding a solution of MeOH, DIPEA and CH_2Cl_2 (20 mL, 10 : 5 : 85) and bubbled with argon for 1 h. The resin was washed with DMF (3 x 10 mL) then CH_2Cl_2 (3 x 10 mL) and dried under a positive pressure of argon. A small portion of resin was then used to ascertain the loading. Estimation of loading level of first residue onto resin (0.16 mmol g^{-1}) was calculated via an Fmoc loading test, as described by Gude *et al.*²²

Standard Fmoc SPPS protocol was used to extend the peptide to the linear Fmoc-Thr-Ile-Gly-Ser stage. Specifically, loaded resin (1.56 g, 0.25 mmol) was added to a manual SPPS vessel and bubbled in DMF (15 mL) for 15 min to swell. The solvent was discharged and the resin was bubbled in an Fmoc deprotection solution of 20% piperidine in DMF (3 x 15 mL, 2 x 1 min then 1 x 5 min) with argon. The resin was washed with DMF (3 x 15 mL) and a coupling solution of amino acid (5 equiv), HATU (5 equiv) and DIPEA (10 equiv) in DMF (15 mL) was added. The solution was then bubbled with argon for 1 h, before the solution was discharged and the resin washed with DMF (3 x 15 mL). The process was repeated to obtain on-resin linear Fmoc-tetrapeptide. An allyl deprotection solution of tetrakis(triphenylphosphine) palladium (578 mg, 0.500 mmol) and phenylsilane (308 μ L, 2.50 mmol) in CH_2Cl_2 and DMF (1:1, 20 mL) was added. The solution was bubbled with argon for 2 h in darkness, after which the deprotection solution was discharged and the resin was washed with DMF (3 x 15 mL), 0.5% sodium diethyldithiocarbamate solution in DMF (4 x 15 mL), DMF (4 x 15 mL) and CH_2Cl_2 (4 x 15 mL). The resin was dried under argon, then added to a 100 mL flame dried round bottom flask under argon. Dry dichloroethane (50 mL), benzoyl chloride (30 μ L, 0.258 mmol), triethylamine (139 μ L, 9.97 mmol) and catalytic DMAP (3.00 mg, 24.6 μ mol) were added. The mixture was stirred overnight at 60 °C. The reaction was cooled to room temperature before the resin was filtered through a manual SPPS vessel and washed with DMF (3 x 15 mL) and CH_2Cl_2 (3 x 15 mL) and dried under argon. To ascertain a successful macrolactonisation, a small sample was cleaved using 2% TFA solution in CH_2Cl_2 (1 mL). The cleavage cocktail was gently agitated for 1 h and filtered through a glass wool plug. The filtrate was concentrated with a gentle stream of argon before being analyzed by LC-MS. Desired cyclic product was identified ($[\text{M}+\text{H}]^+$ calculated for $\text{C}_{30}\text{H}_{36}\text{N}_4\text{O}_8$ 581.2, found (LC-MS) 581.4. Following this modified Yamaguchi esterification, Fmoc SPPS was continued using the above protocol to complete the linear peptide portion. The resin was then divided and the lipid tails were attached to the *N*-terminus using the same procedure (0.05 mmol scale). Acetylated brevicidine (**11**) was synthesized by adding on-resin peptide (306 mg, 50.0 μ mol) to a manual SPPS vessel with DMF (5 mL) to swell for 10 min. The solvent was discharged and a solution of acetic anhydride (240 μ L, 2.54 mmol), DIPEA (440 μ L, 2.53 mmol) and DMAP (1 crystal) in DMF (5 mL) was added and bubbled for 2.5 h with argon. The resin was then washed with DMF (3 x 5 mL) and CH_2Cl_2 (3 x 5 mL) then dried under argon. The dried resin was then added to a cleavage cocktail of TFA, TIPS and distilled water (3 mL, 95 : 2.5 : 2.5) and heated to 37 °C for 1 h. The suspension was filtered through a glass wool plug and the filtrate concentrated under vacuum. Diethyl ether was used to precipitate the crude peptide, which was then centrifuged and washed with additional diethyl ether. The suspension was centrifuged and the pellet dissolved in the minimal amount of 1:1 acetonitrile and water solution with 0.1% TFA. The crude mixture was subsequently purified by RP-HPLC Method A. Fractions were assessed by LC-MS and product containing fractions were pooled, frozen and lyophilized to yield the lipid analogues.

Laterocidine analogues. Rink amide MBHA (5.00 g, 0.67 mmol g^{-1}) was loaded via the sidechain carboxyl group of Fmoc-Asp-Oallyl (2.65 g, 6.70 mmol) with BOP (2.96 g, 6.70 mmol) and DIPEA (2.33 mL, 13.4 mmol) in DMF (150 mL) overnight. The resin was capped with acetic anhydride and pyridine (3 : 2) for 30 min and the resin loading was determined as above (0.50 mmol g^{-1}). Two batches of the loaded resin (1.00 g, 0.500 mmol) were bubbled in tetrakis(triphenylphosphine) palladium (150 mg, 0.130 mmol) and phenylsilane (1.50 mL,

12.2 mmol) in CH_2Cl_2 (30 mL) with nitrogen for 1 h. The resin was subsequently washed with CH_2Cl_2 (5 x 20 mL), sodium diethyldithiocarbamic acid trihydrate in DMF (5 mg mL^{-1} , 5 x 20 mL) and DMF (5 x 20 mL). TFA· H_2N -Gly-OAllyl (230 mg, 1.00 mmol) was coupled using BOP (442 mg, 0.999 mmol) and DIPEA (350 μL , 2.01 mmol) under nitrogen flow for 1 h. Fmoc SPPS was continued using a similar procedure as above: Fmoc was removed using a 20% piperidine solution (3 x 10 mL, 2 x 2 min then 1 x 10 min). The resin was washed and a coupling solution of amino acid (4 equiv), BOP (4 equiv) and DIPEA (8 equiv) in DMF (10 mL) was added and bubbled with nitrogen for 1 h. The process was repeated to extend the N-terminus to include Trp8. The resin was then treated with Alloc-Gly-OH (1.20 g, 7.54 mmol), DIC (1.20 mL, 7.66 mmol) and DMAP (30.0 mg, 0.246 mmol) in CH_2Cl_2 and DMF (16 mL, 3 : 1) under nitrogen for 18 h. Alloc protecting groups were removed following the aforementioned protocol with tetrakis(triphenylphosphine) palladium. Cyclization was then achieved by adding a solution of BOP (442 mg, 0.999 mmol) and DIPEA (350 μL , 2.01 mmol) in DMF (10 mL) and bubbling with nitrogen for 2 h. The remaining linear N-terminal section of the peptide was synthesized using the above SPPS protocol. The two batches of resin were divided and lipid tails were attached as above on a 0.1 mmol scale. Dried resin was subsequently added to cleavage cocktail containing TFA, TIPS and H_2O (5 mL, 95 : 2.5 : 2.5) for 1.5 h. The reaction mixture was then filtered through cotton and precipitated in MTBE and petroleum ether (1 : 1). The resulting precipitate was washed with fresh MTBE and petroleum ether (1 : 1) and lyophilized from *t*-butanol and water (1 : 1). The crude peptide was then purified by RP-HPLC Method B. Pure fractions were pooled and lyophilized.

Purification and analysis of peptides

Prep RP-HPLC purification of crude peptides. Brevicidine analogues were purified by Reversed-Phase High Performance Column Chromatography (RP-HPLC). Purification was performed on a Perkin Elmer HPLC system composed of a 200 series binary pump, UV/Vis detector, vacuum degasser, Rheodyne 7725i injector. The system was operated using ThermoFisher Chromeleon 7.2 software. **Method A (Preparative):** Phenomenex Luna C18 column (5 μm , 250 x 21.2 mm) equipped with a 2 mL sample loop. Runs were performed at a flow rate of 10 mL/min with UV detection at 220 nm. Solvent A = 0.1 % TFA in MilliQ water and solvent B = 0.1 % TFA in MeCN. A gradient method for $\text{C}_0 - \text{C}_{12}$ brevicidine analogues was employed, starting from 5 % B and 95 % A for 5 min, ramping up to 8 % B over 20 min, then ramping up to 20 % B over 15 min, ramping up to 30 % B over 3 min, ramping again up to 95 % B over 4 min, remaining at 95 % B for 3 min, ramping down to 5 % B over 2 min before staying at 5 % B for 5 min. A gradient method for $\text{C}_{14} - \text{C}_{16}$ brevicidine analogues was employed, starting from 5 % B and 95 % A for 5 min, ramping up to 27 % solvent B over 6 min, then ramping up to 44 % solvent B over 7 min, ramping up again to 78 % solvent B over 9 min, ramping to 95 % solvent B over 3 min, remaining at 95 % B for 2 min before ramping down to 5 % B over 3 min and remaining there for 5 min. **Method B (Preparative):** Purification was performed on a BESTA-Technik system with a Dr. Maisch ReproSil Gold 120 C18 column (10 μm , 25 x 250 mm) and equipped with a ECOM Flash UV detector. Runs were performed at a flow rate of 12 mL/min with UV detection at 214 nm and 254 nm. Solvent A = 0.1% TFA in water/MeCN (95 : 5) and solvent B = 0.1% TFA in water/MeCN (5 : 95). A gradient method was employed, starting at 100 % solvent A for 5 min, ramping up to 70 % solvent B over 50 min, remaining at 70 % solvent B for 3 min before ramping down to 100 % solvent A over 1 min and remaining there for 5 min. Product containing fractions

were pooled, partially concentrated under vacuum, frozen and then lyophilized to yield pure peptides as white flocculent solids. A small amount of purified peptide was analyzed by analytical HPLC. **Method C (Analytical):** Analytical runs of brevicidine analogues were performed on a Perkin Elmer HPLC system composed of a 200 series quaternary pump, UV/Vis detector, vacuum degasser, Rheodyne 7725i injector equipped with a 200 μ L sample loop and Phenomenex Luna C18 column (5 μ m, 150 x 4.6 mm). The system was operated using ThermoFisher Chromeleon 7.2 software. Runs were performed at a flow rate of 2 mL/min with UV detection at 220 nm. Solvent A = 0.1 % TFA in MilliQ water and solvent B = 0.1 % TFA in MeCN. A gradient method was employed, starting from 20 % B and 80 % A for 2 min, ramping up to 95 % B over 18 min, ramping down to 20 % B over 0.1 min before staying at 20 % B for 3.9 min. **Method D (Analytical):** Analytical runs of laterocidine analogues were performed on a Shimadzu Prominence-i LC-2030 system with a Dr. Maisch ReproSil Gold 120 C18 (5 μ m, 4.6 x 250 mm) at 30 °C. Runs were performed at a flow rate of 1 mL/min with UV detection at 214 nm and 254 nm. Solvent A = 0.1% TFA in water/CAN (95 : 5) and solvent B = 0.1% TFA in water/CAN (5 : 95). A gradient method for C₀ - C₁₂ laterocidine was employed, starting at 100% solvent A for 2 min, ramping up to 50 % Solvent B over 45 min, ramping up to 100% solvent B over 1 min, remaining at 100% solvent B for 6 min before ramping down to 100% solvent A over 1 min and remaining there for 5 min. A gradient method for C₁₄ - C₁₆ laterocidine was employed, starting at 100% solvent A for 2 min, ramping up to 70 % solvent B over 45 min, ramping up to 100% solvent B over 1 min, remaining there for 6 min before ramping down to 100% solvent A and remaining there for 5 min. High resolution mass spectrometry (HRMS) spectra of brevicidine peptides were recorded by Analytical Services and Environmental Projects (ASEP) at Queen's University Belfast on a Waters LCT Premier ToF mass spectrometer using the electrospray ionisation (ESI) technique. HRMS spectra of laterocidine peptides were performed on a Thermo Scientific Dionex UltiMate 3000 HPLC system with a Phenomenex Kinetex C18 (2.6 μ m, 2.1 x 150 mm) column at 35 °C and equipped with a diode array detector. The following solvent system, at a flow rate of 0.3 mL/min, was used: solvent A = 0.1% formic acid in water, solvent B = 0.1% formic acid in acetonitrile. A gradient method was employed, starting at 95 % solvent A and 5 % solvent B for 1 min, ramping up to 95 % solvent B over 9 min, ramping up to 98 % solvent B over 1 min, remaining there for 1 min before ramping back down to 95 % solvent A over 2 min and remaining there for 1 min. The system was connected to a Bruker micrOTOF-Q II mass spectrometer (ESI ionization) calibrated internally with sodium formate. (HPLC traces of the peptides can be found in the online supplementary material at <https://doi.org/10.1039/D2MD00281G>)

Antimicrobial testing

All minimum inhibitory concentrations (MICs) were determined according to Clinical and Standards Laboratory Institute (CLSI) guidelines. Blood agar plates were inoculated with glycerol stocks of *E. coli* ATCC 25922, *K. pneumoniae* ATCC 13883, *A. baumannii* ATCC 17961, *P. aeruginosa* PAO1 and *S. aureus* USA300. The inoculated agar plates were then incubated for 16 h at 37 °C. Individually grown colonies were subsequently used to inoculate 5 mL aliquots of TSB that were then incubated at 37 °C with shaking at 220 rpm. *E. coli* 25922 MCR-1 glycerol stock was used to inoculate 5 mL of TSB supplemented with kanamycin that was then incubated for 16 h at 37 °C with shaking at 220 rpm. The next day the culture was diluted 100 fold in TSB supplemented with kanamycin and incubated at 37 °C with shaking

at 220 rpm. In parallel, the lipopeptide antibiotics DMSO stocks to be assessed were serially diluted with MHB in polypropylene 96-well plates (50 μL in each well). Colistin sulfate stocks were dissolved in water before being diluted with MHB. Aliquots of the inoculated TSB were incubated until an OD_{600} of around 0.5 was reached. The bacterial suspensions were then diluted with MHB (2×10^5 CFU mL^{-1}) and added to the microplates containing the test compounds (50 μL to each well). The well-plates were sealed with an adhesive membrane and after 18 h of incubation at 37 °C with shaking at 600 rpm, the wells were visually inspected for bacterial growth. MIC values reported are based on three technical replicates and defined as the lowest concentration of the compound that prevented visible growth of bacteria.

Hemolytic assays

Experiments were performed in triplicate and Triton X-100 used as a positive control. Red blood cells from defibrinated sheep blood obtained from Thermo Fisher were centrifuged (400 g for 15 min at 4°C) and washed with Phosphate-Buffered Saline (PBS) containing 0.002% Tween20 (buffer) five times. Then, the red blood cells were normalized to obtain a positive control read-out between 2.5 and 3.0 at 415 nm to stay within the linear range with the maximum sensitivity. A serial dilution of the compounds (128 – 1 $\mu\text{g}/\text{mL}$, 75 μL) was prepared in a 96-well polypropylene plate. The outer border of the plate was filled with 75 μL buffer. Each plate contained a positive control (0.1% Triton-X final concentration, 75 μL) and a negative control (buffer, 75 μL) in triplicate. The normalized blood cells (75 μL) were added and the plates were incubated at 37 °C for 1 h while shaking at 500 rpm. A flat-bottom polystyrene plate with 100 μL buffer in each well was prepared. After incubation, the plates were centrifuged (800 g for 5 min at room temperature) and 25 μL of the supernatant was transferred to their respective wells in the flat-bottom plate. The values obtained from a read-out at 415 nm were corrected for background (negative control) and transformed to a percentage relative to the positive control.

Yields and HRMS analysis of peptides

Table 2. Peptide number, name, chemical formula, exact mass, mass found and overall yield for peptides 1 – 26.

Peptide	Name	Chemical Formula	Calcd Exact Mass	Mass found	Calcd	Overall Yield [%]
1	Brevicidine	C ₇₄ H ₁₀₆ N ₁₈ O ₁₇	1518.7983	507.2688 [M+3H] ³⁺	507.2734	9
9	H-Brev	C ₆₇ H ₉₄ N ₁₈ O ₁₆	1406.7095	704.3672 [M+2H] ²⁺	704.3620	2
10	C2-Brev	C ₆₉ H ₉₆ N ₁₈ O ₁₇	1448.7201	1449.7290 [M+H] ⁺	1449.7274	3
11	C4-Brev	C ₇₄ H ₁₀₀ N ₁₈ O ₁₇	1476.7514	1477.7579 [M+H] ⁺	1477.7592	25
12	C6-Brev	C ₇₃ H ₁₀₄ N ₁₈ O ₁₇	1504.7827	1505.8070 [M+H] ⁺	1505.7905	19
13	C8-Brev	C ₇₅ H ₁₀₈ N ₁₈ O ₁₇	1532.8140	1533.8483 [M+H] ⁺	1533.8218	4
14	C10-Brev	C ₇₇ H ₁₁₂ N ₁₈ O ₁₇	1560.8453	521.2809 [M+3H] ³⁺	521.2809	4
15	C12-Brev	C ₇₉ H ₁₁₆ N ₁₈ O ₁₇	1588.8766	795.4525 [M+2H] ²⁺	795.4456	3
16	C14-Brev	C ₈₁ H ₁₂₀ N ₁₈ O ₁₇	1616.9079	809.4640 [M+2H] ²⁺	809.4612	2
17	C16-Brev	C ₈₃ H ₁₂₄ N ₁₈ O ₁₇	1644.9392	823.4837 [M+2H] ²⁺	823.4769	4
2	Laterocidine	C ₇₈ H ₁₁₃ N ₁₉ O ₁₈	1603.8511	802.9326 [M+2H] ²⁺	802.9329	2
18	H-Lat	C ₆₉ H ₉₇ N ₁₉ O ₁₇	1463.7310	732.8731 [M+2H] ²⁺	732.8728	2
19	C2-Lat	C ₇₁ H ₉₉ N ₁₉ O ₁₈	1505.7415	753.8783 [M+2H] ²⁺	753.8781	1
20	C4-Lat	C ₇₃ H ₁₀₃ N ₁₉ O ₁₈	1533.7728	767.8944 [M+2H] ²⁺	767.8937	3
21	C6-Lat	C ₇₅ H ₁₀₇ N ₁₉ O ₁₈	1561.8041	781.9097 [M+2H] ²⁺	781.9094	2
22	C8-Lat	C ₇₇ H ₁₁₁ N ₁₉ O ₁₈	1589.8354	795.9254 [M+2H] ²⁺	795.9250	2
23	C10-Lat	C ₇₉ H ₁₁₅ N ₁₉ O ₁₈	1617.8667	809.9410 [M+2H] ²⁺	809.9407	3
24	C12-Lat	C ₈₁ H ₁₁₉ N ₁₉ O ₁₈	1645.8980	823.9567 [M+2H] ²⁺	823.9563	0.4
25	C14-Lat	C ₈₃ H ₁₂₃ N ₁₉ O ₁₈	1673.9293	851.9881 [M+2H] ²⁺	851.9876	1
26	C16-Lat	C ₈₅ H ₁₂₇ N ₁₉ O ₁₈	1701.9606	837.9722 [M+2H] ²⁺	837.9720	1

References

- (1) O'Neill, J. *Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations.*; 2014.
- (2) Murray, C. J.; Ikuta, K. S.; Sharara, F.; Swetschinski, L.; Robles Aguilar, G.; Gray, A.; Han, C.; Bisignano, C.; Rao, P.; Wool, E.; Johnson, S. C.; Browne, A. J.; Chipeta, M. G.; Fell, F.; Hackett, S.; Haines-Woodhouse, G.; Kashef Hamadani, B. H.; Kumaran, E. A. P.; McManigal, B.; Agarwal, R.; Akech, S.; Albertson, S.; Amuasi, J.; Andrews, J.; Aravkin, A.; Ashley, E.; Bailey, F.; Baker, S.; Basnyat, B.; Bekker, A.; Bender, R.; Bethou, A.; Bielicki, J.; Boonkasidecha, S.; Bukosia, J.; Carvalho, C.; Castañeda-Orjuela, C.; Chansamouth, V.; Chaurasia, S.; Chiurchiù, S.; Chowdhury, F.; Cook, A. J.; Cooper, B.; Cressey, T. R.; Criollo-Mora, E.; Cunningham, M.; Darboe, S.; Day, N. P. J.; De Luca, M.; Dokova, K.; Dramowski, A.; Dunachie, S. J.; Eckmanns, T.; Eibach, D.; Emami, A.; Feasey, N.; Fisher-Pearson, N.; Forrest, K.; Garrett, D.; Gastmeier, P.; Giref, A. Z.; Greer, R. C.; Gupta, V.; Haller, S.; Haselbeck, A.; Hay, S. I.; Holm, M.; Hopkins, S.; Iregbu, K. C.; Jacobs, J.; Jarovsky, D.; Javanmardi, F.; Khorana, M.; Kissoon, N.; Kobeissi, E.; Kostyanov, T.; Krapp, F.; Krumkamp, R.; Kumar, A.; Kyu, H. H.; Lim, C.; Limmathurotsakul, D.; Loftus, M. J.; Lunn, M.; Ma, J.; Mturi, N.; Munera-Huertas, T.; Musicha, P.; Mussi-Pinhata, M. M.; Nakamura, T.; Nanavati, R.; Nangia, S.; Newton, P.; Ngoun, C.; Novotney, A.; Nwakanma, D.; Obiero, C. W.; Olivás-Martínez, A.; Olliaro, P.; Ooko, E.; Ortiz-Brizuela, E.; Peleg, A. Y.; Perrone, C.; Plakkal, N.; Ponce-de-Leon, A.; Raad, M.; Ramdin, T.; Riddell, A.; Roberts, T.; Robotham, J. V.; Roca, A.; Rudd, K. E.; Russell, N.; Schnall, J.; Scott, J. A. G.; Shivamallappa, M.; Sifuentes-Osornio, J.; Steenkeste, N.; Stewardson, A. J.; Stoeva, T.; Tasak, N.; Thaiprakong, A.; Thwaites, G.; Turner, C.; Turner, P.; van Doorn, H. R.; Velaphi, S.; Vongpradith, A.; Vu, H.; Walsh, T.; Waner, S.; Wangrangsimakul, T.; Wozniak, T.; Zheng, P.; Sartorius, B.; Lopez, A. D.; Stergachis, A.; Moore, C.; Dolecek, C.; Naghavi, M. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. *Lancet* **2022**, 399 (10325), 629–655. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0).
- (3) Shukla, R.; Lavore, F.; Maity, S.; Derks, M. G. N.; Jones, C. R.; Vermeulen, B. J. A.; Melcrová, A.; Morris, M. A.; Becker, L. M.; Wang, X.; Kumar, R.; Medeiros-Silva, J.; van Beekveld, R. A. M.; Bonvin, A. M. J. J.; Lorent, J. H.; Lelli, M.; Nowick, J. S.; MacGillavry, H. D.; Peoples, A. J.; Spoering, A. L.; Ling, L. L.; Hughes, D. E.; Roos, W. H.; Breukink, E.; Lewis, K.; Weingarth, M. Teixobactin Kills Bacteria by a Two-Pronged Attack on the Cell Envelope. *Nature* **2022**, 608 (7922), 390–396. <https://doi.org/10.1038/s41586-022-05019-y>.
- (4) Wang, Z.; Koirala, B.; Hernandez, Y.; Zimmerman, M.; Brady, S. F. Bioinformatic Prospecting and Synthesis of a Bifunctional Lipopeptide Antibiotic That Evades Resistance. *Science* (80-.). **2022**, 376 (6596), 991–996. <https://doi.org/10.1126/science.abn4213>.
- (5) Acedo, J. Z.; Chiorean, S.; Vederas, J. C.; van Belkum, M. J. The Expanding Structural Variety among Bacteriocins from Gram-Positive Bacteria. *FEMS Microbiology Reviews*. Oxford Academic November 1, 2018, pp 805–828. <https://doi.org/10.1093/femsre/fuy033>.
- (6) Kralt, B.; Moreira, R.; Palmer, M.; Taylor, S. D. Total Synthesis of A54145 Factor D. *J. Org. Chem.* **2019**, 84 (18), 12021–12030. https://doi.org/10.1021/ACS.JOC.9B01938/SUPPL_FILE/JO9B01938_SI_002.CIF.
- (7) Noden, M.; Moreira, R.; Huang, E.; Yousef, A.; Palmer, M.; Taylor, S. D. Total Synthesis of Paenibacterin and Its Analogues. *J. Org. Chem.* **2019**, 84 (9), 5339–5347. <https://doi.org/10.1021/acs.joc.9b00364>.
- (8) Cochrane, S. A.; Vederas, J. C. Lipopeptides from Bacillus and Paenibacillus Spp.: A Gold Mine of Antibiotic Candidates. *Med. Res. Rev.* **2016**, 36 (1), 4–31. <https://doi.org/10.1002/MED.21321>.
- (9) Kaneda, T. Iso- and Anteiso-Fatty Acids in Bacteria: Biosynthesis, Function, and Taxonomic Significance. *Microbiol. Rev.* **1991**, 55 (2), 288–302. <https://doi.org/10.1128/mr.55.2.288-302.1991>.
- (10) Cochrane, S. A.; Lohans, C. T.; Brandelli, J. R.; Mulvey, G.; Armstrong, G. D.; Vederas, J. C. Synthesis and Structure-Activity Relationship Studies of N-Terminal Analogues of the Antimicrobial Peptide Tridecaptin A1. *J. Med. Chem.* **2014**, 57 (3), 1127–1131. <https://doi.org/10.1021/jm401779d>.
- (11) Cochrane, S. A.; Surgenor, R. R.; Khey, K. M. W.; Vederas, J. C. Total Synthesis and Stereochemical Assignment of the Antimicrobial Lipopeptide Cerexin A 1. *Org. Lett.* **2015**, 17 (21), 5428–5431. <https://doi.org/10.1021/acs.orglett.5b02779>.
- (12) Sakura, N.; Itoh, T.; Uchida, Y.; Ohki, K.; Okimura, K.; Chiba, K.; Sato, Y.; Sawanishi, H. The Contribution of the N-Terminal Structure of Polymyxin B Peptides to Antimicrobial and Lipopolysaccharide Binding Activity. *Bull. Chem. Soc. Jpn.* **2004**, 77 (10), 1915–1924. <https://doi.org/10.1246/bcsj.77.1915>.
- (13) Li, Y. X.; Zhong, Z.; Zhang, W. P.; Qian, P. Y. Discovery of Cationic Nonribosomal Peptides as Gram-Negative

- Antibiotics through Global Genome Mining. *Nat. Commun.* **2018**, *9* (1). <https://doi.org/10.1038/s41467-018-05781-6>.
- (14) Al Ayed, K.; Ballantine, R. D.; Hoekstra, M.; Bann, S. J.; Wesseling, C. M. J.; Bakker, A. T.; Zhong, Z.; Li, Y. X.; Bröchle, N. C.; van der Stelt, M.; Cochrane, S. A.; Martin, N. I. Synthetic Studies with the Brevicidine and Laterocidine Lipopeptide Antibiotics Including Analogues with Enhanced Properties and in Vivo Efficacy. *Chem. Sci.* **2022**, *13* (12), 3563–3570. <https://doi.org/10.1039/d2sc00143h>.
- (15) Al Ayed, K.; Zamarbide Losada, D.; Machushynets, N. V.; Terlouw, B.; Elsayed, S. S.; Schill, J.; Trebosc, V.; Pieren, M.; Medema, M. H.; van Wezel, G. P.; Martin, N. I. Total Synthesis and Structure Assignment of the Relacidine Lipopeptide Antibiotics and Preparation of Analogues with Enhanced Stability. *ACS Infect. Dis.* **2023**, *9* (4), 739–748. <https://doi.org/10.1021/acscinfecdis.3c00043>.
- (16) Boucher, H. W.; Talbot, G. H.; Bradley, J. S.; Edwards, J. E.; Gilbert, D.; Rice, L. B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. *Clin. Infect. Dis.* **2009**, *48* (1), 1–12. <https://doi.org/10.1086/595011>.
- (17) Gogry, F. A.; Siddiqui, M. T.; Sultan, I.; Haq, Q. M. R. Current Update on Intrinsic and Acquired Colistin Resistance Mechanisms in Bacteria. *Front. Med.* **2021**, *8*, 677720. <https://doi.org/10.3389/fmed.2021.677720>.
- (18) Velkov, T.; Thompson, P. E.; Nation, R. L.; Li, J. Structure–Activity Relationships of Polymyxin Antibiotics. *J. Med. Chem.* **2010**, *53* (5), 1898–1916. <https://doi.org/10.1021/jm900999h>.
- (19) Mukherjee, S.; Van Der Donk, W. A. Mechanistic Studies on the Substrate-Tolerant Lanthipeptide Synthetase ProcM. *J. Am. Chem. Soc.* **2014**, *136* (29), 10450–10459. <https://doi.org/10.1021/ja504692v>.
- (20) Ge, J.; Li, L.; Yao, S. Q. A Self-Immobilizing and Fluorogenic Unnatural Amino Acid That Mimics Phosphotyrosine. *Chem. Commun.* **2011**, *47* (39), 10939–10941. <https://doi.org/10.1039/c1cc14653j>.
- (21) Freire, F.; Fisk, J. D.; Peoples, A. J.; Ivancic, M.; Guzei, I. A.; Gellman, S. H. Diacid Linkers That Promote Parallel β -Sheet Secondary Structure in Water. *J. Am. Chem. Soc.* **2008**, *130* (25), 7839–7841. <https://doi.org/10.1021/ja802042c>.
- (22) Gude, M.; Ryf, J.; White, P. D. An Accurate Method for the Quantitation of Fmoc-Derivatized Solid Phase Supports. *Letts. Pept. Sci.* **2002**, *9* (4–5), 203–206. <https://doi.org/10.1007/BF02538384>.